

# NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

## **Nerviano Medical Sciences Appointed Gergely Balint MSc to Accelerate MPS1 Inhibitor Asset Development**

**NERVIANO, IT and BOSTON, Mass**, 01 February 2023\_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development and maximize the value of its MPS1 Inhibitor Asset, NMS-01940153E (NMS-153).

Gergely is a highly accomplished pharmaceutical industry leader with 25 years of experience in a wide range of operational, strategic and management roles in different cultural and working environments in the EU, US and Asia, leading high performing cross-functional teams to develop clinical/regulatory strategies.

“I am delighted to welcome Gergely to our Global Asset Leadership Team”, said Alessia Montagnoli, Global Head of Asset Leadership of NMS Srl. “His extensive hands-on expertise in global drug development makes him an ideal candidate to drive and explore the full potential of one of our key assets, NMS-153. Targeting a novel mitotic mechanism, NMS-153 has already shown significant clinical activity in patients with unresectable hepatocellular carcinoma who have exhausted standard treatments and might represent a valuable option for cancer patients with hard to treat diseases”

“I’m excited to join NMS and honored to lead the development of its lead asset, NMS-153, a highly selective MPS1 inhibitor with first-in-class potential.” said Gergely Balint. “Together with the project team, my mission will be to bring this innovative asset to the market offering a potential new treatment option, and significantly improve the life of cancer patients, their family and caregivers.”

Gergely was most recently Project Leader/US Office Head at Galapagos leading global late- and early-stage immunology programs and was also responsible for managing the office operations, making executive level decisions and acting as the face and the advocate for Galapagos in the Boston biotechnology community. He previously served as Program Leader at Ipsen and Merck/EMD Serono leading early clinical phase oncology and rheumatology, immunology and neurology assets. Prior to that he worked in clinical operations for 10 years in roles with increasing responsibilities for different pharmaceutical companies and CROs managing global clinical studies of all phases. Gergely holds an MSc degree in Human biology and Neuroscience from the Eötvös Loránd University, Budapest, Hungary and is a certified PMP.

He will be based in Boston, working from the U.S subsidiary (Nerviano Medical Sciences, Inc./ NMS-US).

### **About NMS-01940153E (NMS-153)**

Primary liver cancer is the sixth most common neoplasm and among the leading cause of cancer-related death worldwide. HCC constitutes 80-90% of all primary liver cancers. Its incidence is increasing and will soon surpass one million annual cases worldwide. Most HCC cases are diagnosed at advanced stages and despite the recent approval of new therapeutic agents such as checkpoint inhibitors, there is a high unmet medical need.

# NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

NMS-153 is a highly potent and selective inhibitor of the MPS1 kinase, which is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC.

MPSA-153-001 is a Phase I/II study of NMS-153 administered as single agent in treatment experienced, unresectable HCC patients. [The trial](#) is currently open for enrollment.

## About Nerviano Medical Sciences

[Nerviano Medical Sciences](#) S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing). A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

## About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung [Sidney.dung@nmsgroup.it](mailto:Sidney.dung@nmsgroup.it)